✦ LIBER ✦

Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors

✍ Scribed by Dorte L. Nielsen; Iben Kümler; Jesper A.E. Palshof; Michael Andersson

Book ID: 119210908
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 226 KB
Volume: 22
Category: Article
ISSN: 0960-9776
DOI: 10.1016/j.breast.2012.09.008

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

HER2-targeted therapy in breast cancer.

HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors

✍ Dorte Lisbet Nielsen; Michael Andersson; Claus Kamby 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 303 KB

Her-2/neu and EGFR tyrosine kinase activ

Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer

✍ Gernot Hudelist; Wolfgang J. Köstler; Klaus Czerwenka; Ernst Kubista; Johannes A 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 372 KB 👁 2 views

## Abstract Her‐2/__neu__ overexpression in human breast cancer leads to an aggressive biological behavior and poor prognosis. Although the anti‐Her‐2/__neu__ antibody trastuzumab (Herceptin®) has become a valuable therapeutic option for patients with Her‐2/__neu__‐overexpressing breast cancer, man

Dose escalation and pharmacokinetic stud

Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

✍ Tokuda, Y; Watanabe, T; Omuro, Y; Ando, M; Katsumata, N; Okumura, A; Ohta, M; Fu 📂 Article 📅 1999 🏛 Nature Publishing Group 🌐 English ⚖ 331 KB

Comparison of HER-2 overexpression in pr

Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease

✍ Zidan, J; Dashkovsky, I; Stayerman, C; Basher, W; Cozacov, C; Hadary, A 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 89 KB

Comparison of HER-2 Overexpression in Pr

Comparison of HER-2 Overexpression in Primary Breast Cancer and Metastatic Sites and Its Effect on Biological Targeting Therapy of Metastatic Disease

✍ Hayes, D.F. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 101 KB

Phosphorylated HER-2 tyrosine kinase and

Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC)

✍ Rosa Giuliani; Virginie Durbecq; Angelo Di Leo; Marianne Paesmans; Denis Larsimo 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 636 KB